J. D. Carpeno

IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)

N. Reinmuth, Ying Cheng, A. Mansfield, 2019, Annals of Oncology.

OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC

S. Gettinger, L. Crinò, E. Vokes, 2019, Journal of Thoracic Oncology.

P2.04-10 Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients

N. Viñolas, B. Massuti, M. Provencio, 2019, Journal of Thoracic Oncology.